REVIEW ARTICLE

Shock – Classification and Pathophysiological Principles of Therapeutics

Olga N. Kislitsina1,2,*, Jonathan D. Rich2, Jane E. Wilcox2, Duc T. Pham1, Andrei Churyla1, Esther B. Vorovich2, Kambiz Ghafourian2 and Clyde W. Yancy2

1Department of Cardiac Surgery Bluhm Cardiovascular Institute Feinberg School of Medicine Northwestern University Medical Center, Chicago, Illinois, IL, USA; 2Department of Cardiology Bluhm Cardiovascular Institute Feinberg School of Medicine Northwestern University Medical Center, Chicago, Illinois, IL, USA

Abstract: The management of patients with shock is extremely challenging because of the myriad of possible clinical presentations in cardiogenic shock, septic shock and hypovolemic shock and the limitations of contemporary therapeutic options. The treatment of shock includes the administration of endogenous catecholamines (epinephrine, norepinephrine, and dopamine) as well as various vasopressor agents that have shown efficacy in the treatment of the various types of shock. In addition to the endogenous catecholamines, dobutamine, isoproterenol, phenylephrine, and milrinone have served as the mainstays of shock therapy for several decades. Vasopressin, selepressin, calcium-sensitizing agents like levosimendan, cardiac-specific myosin activators like omecamtiv mectaril (OM), istaroxime, and natriuretic peptides like nesiritide can enhance shock therapy, especially when shock presents a more complex clinical picture than normal. However, their ability to improve clinical outcomes remains to be proven. It is the purpose of this review to describe the mechanism of action, dosage requirements, advantages and disadvantages, and specific indications and contraindications for the use of each of these catecholamines and vasopressors, as well as to elucidate the most important clinical trials that serve as the basis of contemporary shock therapy.

Keywords: Shock, cardiogenic shock, septic shock, shock therapy, endogenous catecholamines, exogenous catecholamines, inotropes, vasopressors.

1. INTRODUCTION

The treatment of cardiogenic shock, septic shock, and hypovolemic shock include the administration of endogenous catecholamines (epinephrine, norepinephrine, and dopamine) as well as various vasopressor agents that have shown efficacy in the treatment of the various types of shock. In addition to the endogenous catecholamines, exogenous catecholamines like Dobutamine, isoproterenol, phenylephrine, and milrinone have served as the mainstays of shock therapy for several decades. Vasopressin, selepressin, calcium-sensitizing agents like levosimendan, cardiac-specific myosin activators like omecamtiv mectaril (OM), istaroxime, and natriuretic peptides like nesiritide can enhance shock therapy, especially when shock presents a more complex clinical picture than normal. However, their ability to improve clinical outcomes remains to be proven. It is the purpose of this communication to describe the mechanisms of action, dosage requirements, advantages/disadvantages, and indications/contraindications for the use of each of these catecholamines and vasopressors and to discuss the importance of the major clinical trials that serve as the basis of contemporary shock therapy.

*Address correspondence to this author at the Center for Heart Failure, Bluhm Cardiovascular Institute Feinberg School of Medicine, Galter Pavilion 11-140, Northwestern University, Chicago, Illinois 60611, IL, USA; Tel: 312-476-8093; Fax: 312-696-1903; E-mail: olga.kislitsina@nm.org

2. CLASSIFICATION OF SHOCK AND GENERAL PRINCIPLES OF TREATING SHOCK

Shock is defined as inadequate organ and peripheral tissue perfusion and is categorized on the basis of its etiology as being either hypovolemic, cardiogenic, or restrictive (vasodilatory/distributive).

In hypovolemic shock, the addition of intravascular volume (preload) combined with drugs specifically capable of increasing LV contractility and stroke volume (SV) can be used to improve cardiac output (CO). Unfortunately, the degree to which the SV can be enhanced pharmacologically is limited by the fact that these drugs also increase the heart rate.

Cardiogenic shock is most commonly caused by an acute myocardial infarction but it can also result from hindrances to adequate cardiac filling such as pericardial tamponade or valvar stenosis. It is characterized by initial hypotension that triggers a vasoconstrictor release to re-establish normal blood pressure (Fig. 1). However, despite the restoration of normal mean arterial pressure (MAP) in both hypovolemic and cardiogenic shock by these compensatory measures, the MVO2 is often decreased in both of these types of “cold shock”. If cardiogenic shock is due to pericardial tamponade, immediate physical intervention to relieve the tamponade is required. However, if cardiogenic shock is due to acute myo-
cardiac infarction, therapy can vary widely depending upon the hemodynamic sequelae of the infarction. Both hypovolemic shock (inadequate preload) and cardiogenic shock (impaired cardiac contractility) are characterized by low left ventricular stroke volume, though unlike hypovolemic shock, cardiogenic shock is often accompanied by an inappropriately slow heart rate.

**Vasodilatory/distributive** shock is characterized by excessive arteriolar vasodilatation that causes a decrease in systemic vascular resistance (SVR) with resultant hypotension that leads to inadequate peripheral perfusion in the presence of warm extremities, hence the term “warm shock”.

**Septic shock** (Fig. 2) is the most common cause of “warm shock” and it is also the most common type of shock overall [1, 2]. Restoration of mean arterial pressure (MAP) is most often achieved by using drugs that increase the SVR. However, initial therapy aimed solely at increasing the SVR may result in only a modest increase in the CO.

Hypovolemic shock is usually the simplest form of shock to treat but many of its treatment strategies do not apply for the other types of shock. Thus, the therapy of shock, regardless of its etiology, demands a thorough knowledge of cardiovascular physiology and the pharmacology of the drugs that are used to treat its derangements.
3. ENDOGENOUS CATCHECHOLAMINES

The endogenous catecholamines epinephrine, norepinephrine, and dopamine all display variable physiologic effects across the dosing range and substantial patient variability in dose–response [1, 3].

4. EPINEPHRINE

Epinephrine (“adrenalin”) is a nonselective agonist of all adrenergic receptors, including the major subtypes $\alpha_1$, $\alpha_2$, $\beta_1$, $\beta_2$, and $\beta_3$. Epinephrine increases SVR via $\alpha_1$ receptor-dependent vasoconstriction (Fig. 3) and increases cardiac output via its binding to $\beta_1$ receptors. As a result, epinephrine is especially useful for the treatment of acute LV failure during cardiac surgery because it predictably increases cardiac output. It is most useful as an inotrope in patients who are hypotensive with no myocardial ischemia, especially following cardiac surgery [3-7].

Epinephrine doses above 0.3-0.5 mcg/kg/min are considered high, but there is no defined maximum epinephrine dose for refractory shock [8, 9]. Unfortunately, the use of epinephrine may be limited because it promotes the development of atrial and ventricular arrhythmias. Another reason for avoiding epinephrine is concern that it may cause elevated lactate levels that could not only be directly harmful but might also confound the serial trending of serum lactate levels [10]. The mechanism of hyperlactemia in sepsis is multifactorial and results from factors beyond hypoxic tissue injury alone [11-13]. Indeed, serum lactic acid levels can be elevated in the presence of adequate systemic perfusion, MAP, and peripheral oxygen delivery [14]. Ven Genderen et al. showed that septic shock behaves differently from other forms of shock in that even when cardiac output and other systemic parameters are optimized, there continues to be a regional microvascular oxygen mismatch [15]. Thus, Rivers et al. warn against using lactate clearance as the only marker of sepsis recovery and state that lactate clearance, central venous oxygen saturation (ScvO$_2$), and other markers represent complementary end points that are not mutually exclusive [16, 17]. However, much like vasopressor-induced sinus tachycardia, elevated lactate may be a beneficial compensatory mechanism [18] by providing a dual action of epinephrine on the heart. Randomized controlled clinical trials have shown that concentrated sodium lactate improves cardiac output among post-CABG and heart failure patients [19, 20].

5. NOREPIHRENINE

Norepinephrine (“noradrenalin”) is an $\alpha_1$-adrenergic receptor agonist with modest $\beta$-agonist activity that makes it a vasoconstrictor but a less potent inotrope. Since norepinephrine is virtually a “pure” vasoconstrictor it may actually reduce CO in patients with cardiac dysfunction because of the strong increase in afterload, although many patients with cardiogenic shock can maintain CO during norepinephrine therapy [21, 22]. Because norepinephrine has minimal chronotropic effects, it is useful in settings in which heart rate
stimulation may be undesirable. Norepinephrine increases both systolic and diastolic blood pressures so it increases coronary blood flow and thus, may improve cardiac function indirectly [23]. Norepinephrine is the first-line vasopressor for all forms of shock with severe hypotension [1, 3, 24].

6. DOPAMINE

Dopamine binds weakly to β-adrenergic receptors but has a high binding affinity at dopamine receptors and at trace amine-associated receptor 1 (TAAR1) [25]. At low doses, dopamine inhibits the release of norepinephrine in peripheral blood vessels, thereby acting as a mild vasodilator. It also inhibits the re-uptake of norepinephrine in presynaptic sympathetic nerve terminals resulting in an indirect increase in cardiac contractility and heart rate. The direct vasodilator effect of dopamine tends to offset the indirect vasoconstriction effect of the secondary increase in norepinephrine so there is usually only a mild increase in SVR. The net effect of the combination of increased contractility, heart rate and only a slight increase in SVR is to improve CO, dramatically so it increases blood pressure [26, 27] but the CO and peripheral tissue perfusion may not continue to improve.

At low doses, dopamine promotes vasodilation and increased blood flow in the coronary, renal, mesenteric and cerebral vascular beds by acting on D1 postsynaptic dopaminergic receptors and it provides additional blood flow to the kidneys by stimulating their D2 presynaptic receptors. Low doses of dopamine (below 4 mcg/kg/min) cause renal vasodilation and natriuretic effects that increase urine output but the impact on creatinine clearance and renal blood flow varies [28-32] and the clinical significance of “renal-dose” dopamine remains unclear. As a result, dopamine is no longer recommended for vasopressor support in septic shock except in patients with bradypressor support who have a low risk of developing tachyarrhythmias [24].

7. COMPARISON OF ENDOGENOUS CATECHOLAMINES

Epinephrine and norepinephrine have equal affinity at both alpha1 and alpha2 receptors. Norepinephrine is slightly lower in potency than epinephrine and approximately 100-fold more potent than dopamine for raising MAP [21, 27, 33, 34]. Epinephrine is more effective than norepinephrine or dopamine in increasing CO in septic shock [7]. In patients with septic shock and a MAP <70 mm Hg despite norepinephrine infusion, adding epinephrine increases MAP, HR, and cardiac index more than adding dobutamine does. Norepinephrine carries a lower tachyarrhythmia risk than either dopamine or epinephrine when used for vasopressor support [27, 34-37]. However, prolonged norepinephrine infusion can have a direct toxic effect on cardiac myocytes by inducing apoptosis via protein kinase A activation and increased cytosolic calcium influx [38]. Likewise, the use of epinephrine in high doses for long periods of time is toxic to arterial walls and causes focal regions of myocardial contraction-band necrosis and myocyte apoptosis [39].

8. EXOGENOUS CATECHOLAMINES

8.1. Dobutamine

Dobutamine directly stimulates β1-receptors and α1 receptors but has a weak affinity for β2 activity, leading to a substantial increase in SV and CO, a moderate increase in HR, and an inconsistent effect on MAP (Fig. 4) [3]. This means that dobutamine is a potent inotrope whose use is less hampered by induced sinus tachycardia than other inotropes.

Fig. (4). Simplified schematic of postulated intracellular actions of β-adrenergic agonist. β-Receptor stimulation, through a stimulatory Gs-GTP unit activates the adenyl cyclase system, which results in increased concentrations of cAMP. In cardiac myocytes, 1-receptor activation through increased cAMP concentration activates Ca2 channels, which leads to Ca2-mediated enhanced chronotropic responses and positive inotropy by increasing the contractility of the actin-myosin-troponin system. In vascular smooth muscle, Ca2 stimulation and increased cAMP results in stimulation of a cAMP-dependent protein kinase, phosphorylation of phospholamban, and augmented Ca2 uptake by the sarcoplasmic reticulum (SR), which leads to vasodilation.
The $\alpha_1$ receptors in vascular smooth muscle, to which dobutamine binds in a combined agonist and antagonist manner, results in a net effect of mild vasodilation, particularly at doses below 5 mcg/kg/min. Furthermore, dobutamine infusions of up to 15 mcg/kg/min increase cardiac contractility without affecting SVR in most patients. However, at higher doses dobutamine causes more vasoconstriction [40]. These varying dose-related reactions to dobutamine by the peripheral vasculature result from the counterbalancing effects of $\alpha_1$-mediated vasoconstriction and $\beta_2$-mediated vasodilation.

Clinically, dobutamine increases cardiac output in patients in shock and heart failure by increasing stroke volume and decreasing SVR. It also increases cerebral oxygenation during hypoxia and/or anemia and may be effective in improving neurological outcomes in ischemic cerebral injury via its action on $\beta_1$-receptors. It may also increase cerebral tolerance to anemia and hypoxia dobutamine [41].

Dobutamine’s effects on MAP can vary considerably because they depend on the relative changes in CO and SVR from baseline values. In cardiogenic shock when the baseline CO is low and SVR is high, dobutamine may raise MAP by increasing the stroke volume (SV) and CO while the SVR declines [3]. However, if the SVR drops too much, the net effect of dobutamine infusion may be hypotension if the CO has not increased proportionately. This can be a particular problem in patients with vasodilatory shock where the baseline CO may already be relatively high in the presence of a low SVR.

The chronotropic response to dobutamine infusion is dose-related and can negate the beneficial effects of increasing the CO in some instances, though as mentioned, this is less of a problem with dobutamine than with other inotropes. At doses up to 5 mcg/kg/min, the SV usually increases without significant tachycardia but above doses of 10 mcg/kg/min the tachycardia worsens without a parallel increase in CO because of the decreased diastolic filling time that limits stroke volume [42]. This problem can often be addressed more effectively by combining low-dose dopamine with low-dose dobutamine rather than by simply increasing the dose of dobutamine [43].

A major advantage of dobutamine in post-cardiotomy patients [44], cardiogenic or septic shock [45] and hypotension following acute MI [46, 47] is that it usually causes a prompt improvement in CO and has a half-life of less than 2 minutes, allowing for the rapid titration and stabilization of optimal infusion rates. Dobutamine should be used with caution in patients with atrial fibrillation because it can increase the velocity of conduction through the atrioventricular (AV) node [48], thereby increasing the likelihood of ventricular fibrillation.

### 8.2. Isoproterenol

Isoproterenol (“Isuprel”) is an analog of epinephrine and a non-selective $\beta$-adrenergic agonist with a low affinity for $\alpha$-adrenergic receptors [49]. Its potential usefulness as a strong inotrope with both systemic and pulmonary vasodilatory actions is limited primarily by its profound chronotropic effect. Isoproterenol is a more potent vasodilator than dobutamine [50], and can be associated with significant improvement in the microcirculation, especially in septic shock where it has been shown to improve both the mixed venous oxygen saturation (SvO2) and cardiac index [51]. Isoproterenol is useful as adjunctive therapy for cardiac arrest, congestive heart failure and all three types of shock.

### 8.3. Phenylephrine

Phenylephrine (“neosynephrine”) is a powerful vasoconstrictor due to its potent $\alpha$-adrenergic activity and its near total lack of affinity for $\beta$-adrenergic receptors. It is useful as an adjunct to inotropic agents in situations where the SVR needs to be increased without significant alterations in other cardiac parameters. According to the Surviving Sepsis Guidelines phenylephrine is contraindicated in patients with septic shock “…. except when 1) Septic shock persists despite the use of 2 or more inotrope/vasopressor agents along with low-dose vasopressin, 2) Cardiac output is known to be high, or 3) Norepinephrine is considered to have already caused serious arrhythmias” [24]. However, in cross-over studies, phenylephrine was shown to be as efficacious as norepinephrine in septic shock patients with a high CO [21, 52]. In addition, it may be useful when septic shock is resistant to maximum levels of dopamine [53].

Phenylephrine is invaluable for the treatment of hypertrophic obstructive cardiomyopathy (HOCM) because it increases the afterload of the left ventricle by increasing the SVR. This enhances the cross-sectional area of the LV outflow tract, thereby decreasing its dynamic gradient during ventricular systole caused by the septal hypertrophy.

### 8.4. Milrinone

The primary advantage of Milrinone over other inotropes is that it increases the heart’s contractility while significantly decreasing both SVR and pulmonary vascular resistance. This unique combination makes it perhaps the most useful drug for the treatment of low output syndrome following cardiac surgery. Milrinone acts by inhibiting phosphodiesterase 3 (PDI), thus mimicking $\beta$-1 and $\beta$-2 activation (Fig. 5) [54].

Milrinone is usually administered either as loading dose of 50 mcg/kg over 10 minutes or it can be initiated at its maintenance dose of 0.5 mcg/kg/min without a loading dose [3, 55]. Milrinone has a longer half-life than most other inotropes and it is quite effective in patients with chronic heart failure who have downregulated or desensitized adrenergic receptors or after long-standing $\beta$-agonist administration. Renal impairment significantly increases the half-life of milrinone so its maintenance dose should be adjusted accordingly in patients with renal failure. Since milrinone does not stimulate $\beta$-1 receptors, its inotropic action persists in the presence of concurrent $\beta$-blockers [56]. Combining milrinone with a direct $\beta$-1 agonist may further increase the CO in patients with severely impaired cardiac function, but this combination is accompanied by more frequent adverse events [57, 58].

Milrinone has also been shown to be effective in acute decompensated heart failure. It is the drug of choice in patients with high SVR and low CO, but caution must be exercised in patients with low SVR or hypovolemia, such as
those in shock, because Milrinone administration may make them too hypotensive [3].

9. VASOPRESSORS AND OTHER AGENTS

9.1. Vasopressin

Vasopressin, or antidiuretic hormone (ADH), contains arginine and for that reason, it is also known as arginine vasopressin (AVP) or argipressin [59]. Vasopressin is a V1a, V1b, and V2 receptor agonist and its two primary actions are vasoconstriction and the maintenance of homeostasis through fluid conservation and the regulation of glucose and salt levels in the blood [60, 61]. Because vasopressin can reduce pulmonary vascular resistance (PVR) while simultaneously increasing SVR, it can be very effective in post-cardiac surgery patients, especially those with right ventricular failure [62, 63], particularly when combined with milrinone.

Vasopressin also causes an increase in vascular sensitivity to norepinephrine which can augment its pressor effects that, fortunately, are preserved during the hypoxic and acidic conditions in shock patients. Low vasopressin doses (0.03-0.04 U/min) can also restore the relative vasopressin deficiency that often develops in shock, resulting in an improvement in MAP and the reduction of catecholamine requirements [3, 64-66]. It is useful in vasodilatory shock following LVAD placement [67] and after cardiac transplantation [68]. On the other hand, higher vasopressin doses can cause mesenteric ischemia and should be used only as salvage therapy in patients with refractory vasodilatory shock [24, 69-71].

9.2.Selepressin

Selepressin, a novel, selective vasopressin V1A receptor agonist, is a potent vasopressor, and it has also been shown to reduce fluid requirements and limit edema formation in animal septic shock models [72-75] and is now in clinical development for the treatment of septic shock. In a phase I first-in-human trial, selepressin infusion in 30 healthy subjects with infusion rates up to 3.0 ng/kg/minute for 6 h showed V1A-agonistic vasopressor properties, was safe and well tolerated, and showed no signs of vasopressin V2 activity. In the first-in-patient pilot phase IIa randomized, placebo-controlled trial, the hypothesis was that selepressin maintains adequate arterial pressure in the absence of norepinephrine and shortens the duration of organ dysfunction in patients with early septic shock. It has been shown that selepressin at an infusion rate of 2.5 ng/kg/minute rapidly replaced norepinephrine while maintaining target MAP and may have improved fluid balance and shortened the time of mechanical ventilation. Further studies of selepressin’s mechanism of action and additional larger randomized controlled trials to investigate its efficacy are needed and ongoing to assess its ability to improve the treatment outcome of patients in septic shock [76].

9.3. Calcium-sensitizing Agents

Levosimendan is an inotropic agent with vasodilator properties that is especially effective for the treatment of patients with acutely decompensated heart failure. Its inotropic properties come from its ability to sensitize the myocardium to calcium by binding to cardiac troponin C. Its vasodilatory effect is the result of opening ATP-sensitive potassium channels in vascular smooth muscle to cause smooth muscle relaxation. The combination of increased cardiac contraction and peripheral vasodilation decrease both preload and afterload, thus improving cardiac output. Levosimendan also has a cardioprotective effect because it opens the mitochondrial ATP-sensitive potassium channels in cardiac muscle [77] (Fig. 6). These unique characteristics of levosimendan allow the myocardium to contract more vigorously without a commensurate increase in its oxygen requirements [78] and without impairing diastolic relaxation [79]. It also has anti-inflammatory [80], antioxidative [81], and anti-apoptotic [82] properties and decreases ischemic reperfusion injury [83].

Levosimendan is also effective in the presence of sepsis and septic shock. It improves microcirculatory flow, renal function, hepatic function and overall hemodynamics better than dobutamine in patients with septic shock [84, 85]. Levosimendan is also used for the treatment of cardiogenic shock due to its profound effect on the CI but is of limited
value because of its vasodilatory effects on both the systemic and pulmonary vascular beds [86]. While levosimendan does not increase the risk of ischemic episodes or tachyarrhythmias in patients with cardiogenic shock [87], its effectiveness as sole therapy is limited in patients with a systolic blood pressure <90 mm Hg [87]. Nevertheless, when combined with other adjunctive therapies such as norepinephrine or balloon counterpulsation, levosimendan may be useful in patients with cardiogenic shock [88].

The question of whether using levosimendan improves outcomes in patients undergoing cardiac surgery requiring cardiopulmonary bypass (CPB) has no definitive answer because the pertinent study results have been mixed. The 2007 SURVIVE trial, which compared levosimendan to dobutamine in CPB patients, failed to show any mortality advantage of levosimendan despite a reduction in plasma B-type natriuretic peptide [89]. Furthermore, the CHEETAH and LEVO-CTS trials showed no advantage in using levosimendan prophylactically to prevent postoperative low output syndrome [90].

However, in other studies, levosimendan was shown to improve the ability to wean patients from CPB, lower inotrope use, decrease myocardial infarction rates, and lower lactate levels when compared to a placebo [91, 92], dobutamine [93], or milrinone [94]. Its salutary effects are more pronounced in patients undergoing CABG surgery with preoperative LV ejection fractions less than 25% [91]. There are many potential reasons for the mixed results of clinical trials with levosimendan [77-79, 86-89] and interestingly, both the LEVO-CT trial and a previous meta-analysis suggested that levosimendan may be beneficial only when administered as high-dose boluses in patients with severe left ventricular dysfunction [90].

9.4. Cardiac-specific Myosin Agents

Omecamtiv mecarbil (OM) enhances myosin crossbridge formation and duration by specifically activating myocardial ATPase and accelerating the transition rate from myosin that is weakly bound to actin into myosin that is strongly bound to actin [95]. This results in a prolongation of systolic ejection time, increased cardiac contractility, and improved energy utilization (steps 3 to 4 in Fig. 7). Delineation of the mechanism of action of OM has provided valuable insights into understanding how the force of cardiac contraction is generated by molecular motors (Fig. 7). OM does not alter myosin morphology per se but rather, it causes an accumulation of cardiac myosin just prior to ventricular systole by binding to the actin filament at more sites and in greater affinity, which in turn, enhances the strength of ventricular contraction. The overall result of OM administration is an increase in left ventricular systolic ejection time, increased sarcomere shortening, and improved stroke volume while leaving the systolic blood pressure unchanged [96]. Importantly, the improvement in cardiac output that results from this combination of OM actions is independent of intracellular calcium and cAMP levels [97, 98]. In order to test the hypothesis that a substance like OM might benefit patients with heart failure who have preserved ejection fraction (HF-rEF), direct activators of cardiac myosin were identified using a reconstituted cardiac sarcomere assay [99]. The initial results of using OM in healthy volunteers and in patients with acute or chronic HF-rEF suggested that OM is safe and that it improves systolic ejection duration and stroke volume without increasing the demand for more ATP energy or oxygen requirements and without altering intracellular calcium levels [99]. However, in the ATOMIC-AHF study, OM did not improve the primary endpoint of dyspnea when compared with placebo and although it appeared to be safe, there seemed to be an improvement in dyspnea only with higher doses of OM [100, 101]. Unfortunately, the OM-treated patients had more episodes of myocardial ischemia, though this difference was not temporally related to OM exposure. There was also a slight increase in plasma troponin in the OM group, though it did not correlate with OM plasma concentrations.

Despite the promising results of preclinical studies [97, 99, 102, 103] and human phase II studies [101], OM has been shown to increase the oxygen demand of the heart [104] and anginal symptoms have been reported at high OM
Fig. (7). The actin–myosin engine and omecamtiv mecarbil. Steps 1 and 2 indicate rapid binding of ATP to the myosin complex allowing the myosin to unbind from actin. Step 3 indicates that, ATP is hydrolyzed into ADP and inorganic phosphate (Pi). This energy allows the myosin head to stretch. Step 4 indicates that, the myosin-ADP-Pi complex bonds to actin in a weakly bound state as it scans for a proper binding site. Step 5 indicates that, once fully attached, the myosin-ADP-Pi strongly bonds to actin, and the release of Pi from the complex causes the myosin head to bend and the actin filament to move. Step 6 indicates that ADP is released and rapidly replaced by ATP, and the cycle is then ready to repeat. Omecamtiv mecarbil accelerates the transition from the weakly bound state to the strongly bound state. (reproduced from Aronson D., et al.) [95].

concentrations. Because of these mixed results, it is suspected that OM may not act exclusively on cardiac β-myosin [105] but that it also opens RyR2 channels causing the release of calcium from the sarcoplasmic reticulum. This could explain the elevated oxygen consumption under baseline conditions reported recently by Bakkehaug et al. [104]. However, it has not been documented that the angina symptoms observed at high OM concentrations [105] are directly related to the known activation of RyR2 receptors by OM. In a recent study, OM was shown to activate ryanodine receptors directly in cardiac muscle but not in skeletal muscle but again, the troponin levels were increased at high doses of OM [106]. Although OM remains promising, further investigations are needed to document that it is safe to use in patients with acute and chronic heart failure and in the presence of reduced ejection fraction. [107]. OM is currently being evaluated in a large Phase 3 trial in patients with HF-rEF (GALACTIC-HF). This trial will compare OM titrated to 50 mg orally twice daily with placebo in patients 18 to 85 years of age with New York Heart Association (NYHA) class II–IV symptoms and an LVEF of 35% or less who are admitted for an HF exacerbation, hospitalized with a prior HF exacerbation, or had an urgent HF admission within the last year. The primary endpoints are cardiovascular death or readmission for HF. While OM has the potential to fill a largely unmet clinical need, the results of Novartis’ PIONEER-HF trial evaluating sacubitril/valsartan in a similar population are expected to be published ahead of GALACTIC-HF. It is important to note that the endpoints for these trials differ, with PIONEER-HF evaluating only N-terminal pro-BNP levels as well as the incidences of hyperkalemia, symptomatic hypotension, and angioedema.

This will give OM an advantage if it can show reduced cardiovascular mortality and rehospitalization [108, 109].

9.5. Istaroxime

Istaroxime inhibits sodium/potassium (Na-K) ATPase and stimulates the calcium ATPase isoform 2a (SERCA2a), causing the sarcoplasmic reticulum to re-uptake calcium during ventricular diastole. This combination of Na-K AT-Phase inhibition and SERCA2a stimulation increases the cardiac output without increasing the heart rate or causing cardiac arrhythmias. In patients with acute heart failure, istaroxime increases the systolic BP and reduces the wedge pressure, heart rate and LV end-diastolic volume [110]. Currently, clinical trials are underway to evaluate the safety and efficacy of Istaroxime in patients with acute heart failure and depressed LV function.

9.6. Natriuretic Peptides

Nesiritide is recombinant human brain natriuretic peptide (BNP) that is a vasodilator, enhances sodium excretion, and suppresses both the renin-angiotensin-aldosterone system and the sympathetic nervous system [111]. In a randomized, controlled trial in patients with acute congestive heart failure, Nesiritide improved dyspnea and reduced the wedge pressure, but it conveyed no mortality benefit in comparison to standard vasoactive drug therapy. In the more recent ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure), nesiritide again had no effect on mortality or rehospitalization for heart failure within 30 days [112]. Nesiritide should be used with
caution in cardiogenic shock because of its propensity to cause hypotension.

10. SPECIFIC DRUGS FOR THE TREATMENT OF SHOCK

10.1. Cardiogenic Shock

In the past two decades, the survival rate for patients with cardiogenic shock following an acute MI has increased from 44% in 1995 [113] to over 50% in 2005 [114], to 67% more recently [115]. Much of that improvement is attributable to the more informed use of inotropes, vasopressors, vasodilators and a variety of new drugs that have become available. Since severe vasodilation resulting from receptor desensitization, inflammation, acidemia, hypocalcemia, and the relative deficiency of vasopressin and corticosteroids is present in most cases of refractory shock [2, 9, 54], an immediate fluid challenge should be the first step in its therapy. This should be followed by the initial administration of weaker inotropes like dobutamine or low-dose epinephrine but if a satisfactory response is not elicited, stronger vasopressors like norepinephrine [116] should be administered [117]. The ACC/AHA guidelines for the management of hypotension complicating acute MI recommend dobutamine as the first-line inotropic agent if the systolic blood pressure is between 70 and 100 mm Hg in the absence of signs and symptoms of shock. However, more recent guidelines recommend a combination of norepinephrine and dobutamine over dopamine for cardiogenic shock [27, 46, 47]. The risk of tachyarrhythmias during inotropic therapy is least with milrinone, intermediate with dobutamine or epinephrine, and highest with dopamine [54, 45].

Dobutamine is also recommended for acute cardiogenic shock with hypotension and for septic shock with myocardial dysfunction, as well as in patients with severe renal failure [3, 47]. Although milrinone produces greater vasodilation and cardiac preload in such patients, dobutamine is preferable because it causes a greater increase in myocardial contractility [118]. However, since milrinone reduces PVR more than dobutamine, it is preferable in patients with significant right ventricular dysfunction. It is also the inotrope of choice in patients with chronic HF, especially in the presence of pulmonary hypertension, right ventricular failure, or β-blocker therapy [3, 119, 120]. The safety and efficacy of levosimendan for the treatment of cardiogenic shock could potentially be clarified by a new randomized clinical trial in patients with low baseline ejection fractions in which the levosimendan is administered only as large-dose boluses. Until such clarification, the potential benefit of levosimendan in cardiogenic shock will remain controversial.

10.2. Vasodilatory/Distributive Shock

In septic shock, norepinephrine is more effective than the combined therapy of dopamine and vasopressin with the addition of phenylephrine in non-responders [35] Several studies have shown dopamine to increase the mortality when it is used as the first-line vasopressor [121]. However, the combination of dopamine and dobutamine at a dose of 7.5 mcg/kg/min each improves cardiac hemodynamics while limiting important side effects better than either individual agent administered at 15 mcg/kg/min [118]. Epinephrine is the vasopressor of choice in septic shock refractory to high-dose norepinephrine, especially when the HR is high or the CO is low [3, 24, 9]. Randomized trials have shown similar mortality with epinephrine or norepinephrine in patients with shock [33, 65]. Epinephrine is approximately 100-fold more potent than dobutamine or dopamine. The CATS trial comparing norepinephrine plus dobutamine to epinephrine alone for patients with septic shock showed similar mortality rates and adverse events at 90 days despite more lactic acidosis in the epinephrine group [21, 27, 33, 52].

Hopefully, these clinical trials and others will confirm that a number of promising new drugs are capable of improving on the current status of therapy for all types of shock.

CONCLUSION

Shock can sometimes be difficult to categorize accurately and is often difficult to treat correctly because of its various etiologies and the multitude of treatment options available. Therapies that are optimal for one type of shock might be harmful in another type, so recognition of the type of shock is critical to successful therapy. In addition, a thorough understanding of the physiology of the various types of shock and of the pharmacology of shock therapy is essential to optimal outcomes.

CONSENT FOR PUBLICATION

Not applicable.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Vincent JL, De Backer D. Circulatory shock. N Engl J Med 2013; 369: 1726-34.
[2] Russell JA. Management of sepsis. N Engl J Med 2006; 355(16): 1699-713.
[3] Hollenberg SM. Vasoactive drugs in circulatory shock. Am J Respir Crit Care Med 2011; 183(7): 847-55.
[4] Sato Y, Matsuzawa H, Eguchi S. Comparative study of effects of adrenaline, dobutamine and dopamine on systemic hemodynamics and renal blood flow in patients following open heart surgery. Jpn Circ J 1982; 46(10): 1059-72.
[5] Butterworth JF, Prielipp RC, Royster RL, et al. Dobutamine increases heart rate more than epinephrine in patients recovering from aortocoronary bypass surgery. J Cardiothorac Vasc Anesth 1992; 6(5): 535-41.
[6] Prielipp RC, MacGregor DA, Royster RL, et al. Dobutamine antagonizes epinephrine’s biochemical and cardiotoxic effects: Results of an in vitro model using human lymphocytes and a clinical study in patients recovering from cardiac surgery. Anesthesiology 1998; 89(1): 49-57.
[7] Mahmoud KM, Ammar AS. Norepinephrine supplemented with dobutamine or epinephrine for the cardiovascular support of patients with septic shock. Indian J Crit Care Med 2012; 16(2): 75-80.
[8] Kleinman ME, Goldberger ZD, Rea T, et al. 2017 American Heart Association focused update on adult basic life support and cardipulmonary resuscitation quality: An Update to the American Heart
Association Guidelines for Cardiac pulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2018; 137: e7-13.

[9] Bassi E, Park M, Azevedo LC. Therapeutic strategies for highdose vasopressor-dependent shock. Crit Care Res Pract 2013; 2013: 654708.

[10] Levy B, Perez P, Perny J, et al. Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med 2011; 39(3): 450-5.

[11] Bolton JD. Clinical use of lactate testing in shock states. Seminars in Anesthesia, Perioperative Medicine and Pain 2007; 26: 35-9.

[12] Kraut JA, Madias NE. Lactic acidosis. N Engl J Med 2014; 371(24): 2309-19.

[13] Levraut J, Ciebiera JP, Chave S, et al. Mild hyperlactatemia in stable septic patients is due to impaired lactate clearance rather than overproduction. Am J Respir Crit Care Med 1998; 157(4 Pt 1): 1021-6.

[14] Gibot S. On the origins of lactate during sepsis. Crit Care 2012; 16: 151.

[15] van Genden ME, Klijn E, Lima A, et al. Microvascular perfusion as a target for fluid resuscitation in experimental circulatory shock. Crit Care Med 2014; 42(2): 969-105.

[16] Chertoff J, Chisum M, Garcia B,. Lactate kinetics in sepsis and septic shock: 2012. Crit Care Med 2013; 41(2): 580.

[17] Rivers EP, Elkin R, Cannon CM. Countopoint: Should lactate clearance be substituted for central venous oxygen saturation as goals of early severe sepsis and septic shock therapy? No. Chest 2011; 140: 1408-13. Discussion 1409-13.

[18] Wutrich Y, Barnaud D, Conrad M, et al. Early increase in arterial lactate concentration under epinephrine infusion is associated with a better prognosis during shock. Shock 2010; 34(1): 4-9.

[19] Nalos M, Leverve X, Huang S, et al. Half-molar sodium lactate infusion improves cardiac performance in acute heart failure: A pilot randomised controlled clinical trial. Crit Care 2014; 18(2): R48.

[20] Leverve XM, Boon C, Hakim T, et al. Half-molar sodium-lactate solution has a beneficial effect in patients after coronary artery bypass grafting. Intensive Care Med 2008; 34(10): 1796-803.

[21] Morelli A, Ertmer C, Rehberg S, et al. Phenytoin versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Crit Care. 2008;12(6): R143.

[22] Maas JJ, Pinsky MR, de Wilde RB, et al. Cardiac output response to norepinephrine in postoperative cardiac surgery patients: interpretation with venous return and cardiac function curves. Crit Care Med 2013; 41(1): 143-50.

[23] Tune JD, Richmond KN, Gorman MW, et al. Control of coronary blood flow during exercise. Exp Biol Med (Maywood) 2002; 227: 238-50.

[24] Delligaper LP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41(2): 580-637.

[25] Grandy DK, Miller GM, Li JJ. ""TAARGettingAddiction""-The alamo bears witness to another revolution: An overview of the plenary symposium of the 2015 behavior, biology and chemistry conference. Drug Alcohol Depend 2016; 159: 9-16.

[26] Browne JB, Knights KM. Pharmacology for Health Professionals (2nd ed.). Elsevier Australia. 2009, p. 192.

[27] De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362(9): 779-89.

[28] Ichai C, Soublije J, Carles M, et al. Meta-analysis: Low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142(7): 510-24.

[29] Unar A, Fumagalli S, Marin M, et al. Renal, but not systemic, hemodynamic effects of dopamine are influenced by the severity of congestive heart failure. Crit Care Med 2004; 32(5): 1125-9.

[30] Juste RN, Panikkar N, Soni N. The effects of low-dose dopamine infusions on hemodynamic and renal parameters in patients with septic shock requiring treatment with noradrenaline. Intensive Care Med 1998; 24(6): 564-8.

[31] Girbes AR, Patten MT, McCloskey BV, et al. The renal and neurohumoral effects of the addition of low-dose dopamine in septic critically ill patients. Intensive Care Med 2000; 26(11): 1658-9.

[32] Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: A randomised trial. Lancet 2007; 370(9588): 676-84.

[33] Myburgh JA, Higgins A, Jovanovska A, et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med 2008; 34(12): 2226-34.

[34] Patel GP, Grahe JS, Sperry M, et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock 2010; 33(4): 375-80.

[35] Levy B, Perez P, Perny J, et al. Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med 2011; 39(3): 450-5.

[36] De Backer D, Creteur J, Silva E, et al. Effects of dopamine, norepinephrine, and epinephrine on the splanchic circulation in septic shock: Which is best? Crit Care Med 2003; 31(6): 1658-67.

[37] Communal C, Singh K, Pimentel DR, et al. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the β1-adrenergic pathway. Circulation 1998; 98: 1329-34.

[38] Romson JL, Leung JM, Bellows WH, et al. Effects of dobutamine on hemodynamics and left ventricular performance after cardiopulmonary bypass in cardiac surgical patients. Anesthesiology 1999; 91(5): 1318-28.

[39] Richard C, Ricome JL, Rimalho A, et al. Combined hemodynamic effects of dopamine and dobutamine in cardiogenic shock. Circulation 1983; 67(3): 620-6.

[40] Butterworth JP, Prielipp RC, Royster RL, et al. Dobutamine increases heart rate more than epinephrine in patients recovering from aortocoronary bypass surgery. J Cardiothorac Vasc Anesth 1992; 6(5): 535-41.

[41] Jentzer J, Coons J, Pharm D, et al. Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit. J Cardiovasc Pharmacol Therapeut 2015; 20(3): 249-60.

[42] Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 109(9): e292-9.

[43] Werdan K, Russ M, Buerke M, et al. Cardiogenic shock due to myocardial infarction: Diagnosis, monitoring and treatment: A German-Austrian S3 Guideline. Deutsch Arztebl Int 2012; 109(19): 343-51.

[44] Volkow ND, Wang GJ, KollinsSH, et al. Evaluating dopamine reward pathway in ADHD: Clinical implications. JAMA 2009; 302(10): 1084-91.

[45] Mozayan A, Raymon L. Handbook of Drug Interactions: A Clinical and Forensic Guide. Springer Science & Business Media. 2003; pp. 541-2.

[46] Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: International guidelines for the management of sepsis and septic shock. Intensive Care Med 2017; 43(3): 304-77.

[47] Leon M, Boyadjiev I, Boulos E, et al. A reappraisal of isoprotorenol in goal-directed therapy of septic shock. Shock 2006; 26(4): 353-7.

[48] Morelli A, Lange M, Ertmer C, et al. Short-term effects of phenylephrine on systemic and regional hemodynamics in patients with septic shock: A crossover pilot study. Shock 2008; 29(4): 446-51.

[49] Jain G, Singh DK. Comparison of phenylephrine and norepinephrine in the management of dopamine-resistant septic shock. Indian J Crit Care Med 2010; 14(1): 29-34.

[50] Bangash MN, King ML, Pearse RM. Use of inotropes and vasopressor agents in critically ill patients. Br J Pharmacol 2012; 165(7): 2015-33.
[55] Burach L, Patacsil P, Hameed A, et al. Pharmacodynamic effects of milrinone with and without a bolus loading infusion. Am Heart J 2001; 141(2): 266-73.

[56] Carceles, MD, Fuentes, T, Aroca V, et al. Effects of milrinone on contractility and cyclic adenosine monophosphate production induced by beta-1 and beta-2-adrenergic receptor activation in human myocardium. Clin Ther 2007; 29: 1718-24.

[57] Rossinen J, Harjola VP, Siirila-Waris K, et al. The use of more than one inotrope in acute heart failure is associated with increased mortality: A multi-centre observational study. Acute Cardiac Care 2008; 10(4): 209-13.

[58] Royston RL, Butterworth JF, Preilipp RC, et al. Combined inotropic effects of amrinone and epinephrine after cardiopulmonary bypass in humans. Anesth Analg 1993; 77(4): 662-72.

[59] Anderson DA (2012).

[60] Caldwell HK, Young WS III. Oxytocin and Vasopressin: Genetics and Behavioral Implications (PDF). In: Lajtha A, Lim R. Handbook of Neurochemistry and Molecular Neurobiology: Neuroactive Proteins and Peptides (3rd ed.). Berlin: Springer. 2006; pp. 573-607.

[61] Babar SM. SIADH associated with ciprofloxacin. Ann Pharmacother 2003; 37(1): 1359-63.

[62] Morell A, Ertmer C, Rohrbach S, et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): A randomized, controlled pilot study. Crit Care 2009; 13(4): R130.

[63] Luckner G, Mayr VD, Joehberger S, et al. Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock. Crit Care Med 2007; 35(10): 2280-5.

[64] Russell JA, Fjell C, Hsu JL, et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. Am J Respir Crit Care Med 2013; 188(3): 356-64.

[65] Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41(2): 580-637.

[66] Polito A, Parisini E, Ricci Z, et al. Vasopressin for treatment of vasodilatory shock: An ESICM systematic review and meta-analysis. Intensive Care Med 2012; 38(1): 9-19.

[67] Argenziano M, Chen JM, Choudbri AF, et al. Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agent. J Thoracic Cardiovasc Surg 1998; 116: 973-80.

[68] Argenziano M, Chen JM, Cullinane S, et al. Cardiac transplantation for end-stage heart disease. Cardiol Rev 1999; 7(6): 349-55.

[69] Torgerensen C, Dunser MW, Wenzel V, et al. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: A randomized, controlled, open-label trial. Intensive Care Med 2010; 36(1): 57-65.

[70] Luckner G, Mayr VD, Joehberger S, et al. Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock. Crit Care Med 2007; 35(10): 2280-5.

[71] Tayama E, Ueda T, Shojima T, et al. Arginine vasopressin is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Crit Care Med 2011; 39(1): 119-25.

[72] Rehberg S, Yamamoto Y, Sousse L, et al. Selective V1α receptor agonism attenuates vascular dysfunction and fluid accumulation in ovine septic shock. Am J Physiol Heart Circ Physiol 2012; 303(10): H1245-54.

[73] Maybauer MO, Maybauer DM, Enkhbaatar P, et al. The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis. Crit Care Med 2014; 42(7): e525-33.

[74] Rehberg S, Ertmer C, Vincent JL, et al. Role of selective V1α receptor agonism in ovine septic shock. Crit Care Med 2011; 39(1): 21-23.

[75] Lehtonen L, Pöder P. The utility of levosimendan in the treatment of heart failure. Ann Med 2007; 39(1): 2-17.

[76] Gordon AC, Perkins GD, Singer M, et al. Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med 2016; 375(17): 1638-48.

[77] Ukkonen H, Saraste M, Akkila J, et al. Myocardial efficiency during calcium sensitization with levosimendan: A noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther 1997; 61: 596-607.

[78] Wang Q, Yokoo H, Takashina M, et al. Anti-inflammatory profile of levosimendan in cecal ligation-induced septic mice and in lipopolysaccharide-stimulated macrophages. Crit Care Med 2015; 43: e508-20.

[79] Hasslacher J, Bijuklic K, Bertocchi C, et al. Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: A prospective observational study. Crit Care 2011; 15: R166.

[80] Paraskevaidis IA, Parissis JT, Kremastinos D. Anti-inflammatory and anti-apoptotic effects of levosimendan in decompensated heart failure: A novel mechanism of drug-induced improvement in contractile performance of the failing heart. Curr Med Chem Cardiovasc Hematol Agents 2005; 3(3): 243-7.

[81] du Toit EF, Genis A, Opie LH, Pollesello P. A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart. Br J Pharmacol 2008; 154(1): 235-40.

[82] Morelli A, Donati A, Ertmer C, et al. Levosimendan for resuscitating the microcirculation in patients with septic shock: A randomized controlled study. Crit Care 2010; 14: R232.

[83] Mennis D, Inal MT, Sut N. The effects of levosimendan vs dobutamine added to dopamine on liver functions assessed with noninvasive liver function monitoring in patients with septic shock. J Crit Care 2012; 27: 318.e1-e6.

[84] Bueree M, Lennm H, Krohe K, et al. Levosimendan in the treatment of cardiogenic shock. Minerva Cardioangiologica 2010; 58(4): 519-30.

[85] Shang G, Yang X, Song D. Effects of levosimendan on patients with heart failure complicating acute coronary syndrome: A meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs 2017; 17: 453.

[86] Russ MA, Prondzinsky R, Christoph A, et al. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med 2007; 35(12): 2732-9.

[87] Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE Randomized Trial. JAMA 2007; 297(17): 1883-91.

[88] Mehta RH, Lomerger JD, van Diepen S, et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery: An expert opinion. Int J Cardiol 2012; 173(2): 125-30.

[89] Toller W, Herlinglake M, Guarracino F, Algotsen L. Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. Int J Cardiol 2015; 184: 323-36.

[90] Levin R, Degrange M, Del Mazo C, et al. Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol 2012; 17(3): 125-30.
[98] Teerlink JR, Metra M, Zacà V, et al. Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart Fail Rev 2009; 14(4): 243-53.

[99] Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 2011; 331(6023): 1439-43.

[100] Teerlink JR, Felker GM, McMurray JJ, et al. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: The ATOMIC-AHF study. J Am Coll Cardiol 2016; 67(12): 1444-55.

[101] Teerlink JR, Felker GM, McMurray JJ, et al. Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-AHF): A phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet 2016; 388(10062): 2895-903.

[102] Utter MS, Ryba DM, Li BH, et al. Omecamtiv mecarbil, a cardiac myosin activator, increases Ca2+ sensitivity in myofilaments with a dilated cardiomyopathy mutant tropomysin E54K. J Cardiovasc Pharmacol 2015; 66(4): 347-53.

[103] Mamidi R, Gresham KS, Li A. Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C. J Mol Cell Cardiol 2015; 85: 262-72.

[104] Bakkehaug JP, Kildal AB, Engstad ET, et al. Myosin activator omecamtiv mecarbil increases myocardial oxygen consumption and impairs cardiac efficiency mediated by resting myosin ATPase activity. Circ Heart Fail 2015; 8: 766-75.

[105] Cledan JGF, Teerlink JR, Senior R, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: A double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 2011; 378: 676-83.

[106] Nánási P Jr, Gaburjakova M, Gaburjakova J, et al. Omecamtiv mecarbil activates ryanodine receptors from canine cardiac but not skeletal muscle. Eur J Pharmacol 2017; 809: 73-9.

[107] Planellés-Herrero VJ, Hartman JJ, Robert-Paganin J, et al. Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil. Nat Commun 2017; 8(1): 190.

[108] Horváth B, Szentandrassy N, Veress R, et al. Frequency-dependent effects of omecamtiv mecarbil on cell shortening of isolated canine ventricular cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol 2017; 390(12): 1239-46.

[109] PharmaPoint: Heart Failure—Global Drug Forecast and Market Analysis to 2026 New York, New York: Global Data. July 2017.

[110] Gheorghiade M, Ambrosy AP, Ferrandi M, et al. Combining SERCA2a activation and Na-K ATPase inhibition: A promising new approach to managing acute heart failure syndromes with low cardiac output. Discov Med 2011; 12(63): 141-51.

[111] Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompenated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000; 343(4): 246-53.

[112] O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365(1): 32-43.

[113] Holmes DR Jr, Bates ER, Kleiman NS, Sadowski Z. Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience. The GUSTO-I Investigators. Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries. J Am Coll Cardiol 1995; 26(3): 668-74.

[114] Babaev A, Frederick PD, Pasta DJ, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2005; 294(4): 448-54.

[115] Anderson ML, Peterson ED, Peng SA, et al. Differences in the profile, treatment, and prognosis of patients with cardiogenic shock by myocardial infarction classification: A report from NCDDR. Circ Cardiovasc Qual Outcomes 2013; 6(6): 708-15.

[116] Martin C, Papazian L, Perrin G, et al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993; 103(6): 1826-31.

[117] Levy B, Dusang B, Annane D, et al. Cardiovascular response to dopamine and early prediction of outcome in septic shock: A prospective multiple-center study. Crit Care Med 2005; 33(10): 2172-77.

[118] Mager G, Kloeke RK, Kux A, et al. Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure. Am Heart J 1991; 121(6 pt 2): 1974-83.

[119] Metra M, Nodari S, D’Alloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: A randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002; 40(7): 1248-58.

[120] Tilley DG, Rockman HA. Role of beta-adrenergic receptor signaling and desensitization in heart failure: new concepts and prospects for treatment. Expert Rev Cardiovasc Ther 2006; 4: 417-32.

[121] Overgaard C, Džavik V. Inotropes and vasopressors review of physiology and clinical use in cardiovascular disease. Circulation 2008; 118: 1047-56.